BioNTech buys CureVac for $1.25 billion to expand into cancer treatments using mRNA technology

From Yahoo Finance: 2025-06-12 10:25:00

BioNTech acquires CureVac for $1.25 billion to expand into cancer treatment using mRNA technology. CureVac shares surge 37% after the all-stock deal announcement. Investors will receive $5.46 worth of BioNTech shares for each CureVac share. The deal aims to develop innovative cancer treatments and establish new care standards.

The deal is expected to close this year, making CureVac a wholly owned subsidiary of BioNTech. CureVac’s stock reaches its highest level since December 2023. BioNTech’s U.S.-listed shares remain down nearly 8% year-to-date. The acquisition signals BioNTech’s move into producing new cancer treatments.

BioNTech co-founder and CEO Dr. Ugur Sahin aims to advance transformative cancer treatments through the acquisition. The transaction marks BioNTech’s expansion into oncology and infectious diseases based on mRNA technology. The company seeks to establish new care standards for various types of cancer in the future.

Read more: COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments